Dynavax Technologies Corporation (DVAX)
USD 11.27
(2.69%)
USD 11.27
(2.69%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 219.14 Million USD | 16.75% |
| 2022 | 178 Million USD | 34.46% |
| 2021 | 132.38 Million USD | 22.73% |
| 2020 | 107.86 Million USD | -21.45% |
| 2019 | 137.31 Million USD | -1.72% |
| 2018 | 139.72 Million USD | 49.36% |
| 2017 | 93.54 Million USD | -23.16% |
| 2016 | 121.75 Million USD | 11.57% |
| 2015 | 109.12 Million USD | 6.62% |
| 2014 | 102.34 Million USD | 31.65% |
| 2013 | 77.73 Million USD | 0.55% |
| 2012 | 77.31 Million USD | 11.73% |
| 2011 | 69.19 Million USD | -3.28% |
| 2010 | 71.53 Million USD | 29.05% |
| 2009 | 55.43 Million USD | -9.44% |
| 2008 | 61.21 Million USD | -28.14% |
| 2007 | 85.18 Million USD | 29.76% |
| 2006 | 65.65 Million USD | 76.74% |
| 2005 | 37.14 Million USD | 17.28% |
| 2004 | 31.67 Million USD | 70.37% |
| 2003 | 18.59 Million USD | -7.45% |
| 2002 | 20.08 Million USD | -8.24% |
| 2001 | 21.89 Million USD | 86.81% |
| 2000 | 11.71 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 55.75 Million USD | -1.16% |
| 2024 Q1 | 56.4 Million USD | 1.82% |
| 2023 Q2 | 50.11 Million USD | -0.06% |
| 2023 Q1 | 50.14 Million USD | 14.31% |
| 2023 Q4 | 55.39 Million USD | 6.19% |
| 2023 Q3 | 52.16 Million USD | 4.09% |
| 2023 FY | 207.83 Million USD | 16.75% |
| 2022 Q2 | 45.86 Million USD | 6.01% |
| 2022 FY | 178 Million USD | 34.46% |
| 2022 Q4 | 43.86 Million USD | -2.52% |
| 2022 Q3 | 45 Million USD | -1.88% |
| 2022 Q1 | 43.26 Million USD | 7.25% |
| 2021 Q3 | 33.11 Million USD | 15.17% |
| 2021 Q2 | 28.75 Million USD | -4.74% |
| 2021 Q4 | 40.34 Million USD | 21.83% |
| 2021 Q1 | 30.18 Million USD | 10.2% |
| 2021 FY | 132.38 Million USD | 22.73% |
| 2020 Q3 | 30.05 Million USD | 21.02% |
| 2020 Q2 | 24.83 Million USD | -2.9% |
| 2020 FY | 107.86 Million USD | -21.45% |
| 2020 Q4 | 27.38 Million USD | -8.89% |
| 2020 Q1 | 25.57 Million USD | -21.51% |
| 2019 FY | 137.31 Million USD | -1.72% |
| 2019 Q1 | 39.55 Million USD | 0.57% |
| 2019 Q2 | 34.05 Million USD | -13.9% |
| 2019 Q3 | 31.11 Million USD | -8.63% |
| 2019 Q4 | 32.58 Million USD | 4.72% |
| 2018 Q3 | 32.6 Million USD | 2.14% |
| 2018 FY | 139.72 Million USD | 49.36% |
| 2018 Q1 | 35.85 Million USD | 28.69% |
| 2018 Q2 | 31.92 Million USD | -10.96% |
| 2018 Q4 | 39.33 Million USD | 20.61% |
| 2017 Q2 | 20.42 Million USD | -10.48% |
| 2017 FY | 93.54 Million USD | -23.16% |
| 2017 Q4 | 27.86 Million USD | 24.14% |
| 2017 Q3 | 22.44 Million USD | 9.88% |
| 2017 Q1 | 22.81 Million USD | -14.26% |
| 2016 Q1 | 28.23 Million USD | 2.19% |
| 2016 Q2 | 31.9 Million USD | 12.98% |
| 2016 Q4 | 26.61 Million USD | -23.96% |
| 2016 Q3 | 35 Million USD | 9.71% |
| 2016 FY | 121.75 Million USD | 11.57% |
| 2015 Q1 | 27.07 Million USD | 9.68% |
| 2015 Q2 | 24.78 Million USD | -8.48% |
| 2015 Q4 | 27.63 Million USD | -6.74% |
| 2015 Q3 | 29.62 Million USD | 19.55% |
| 2015 FY | 109.12 Million USD | 6.62% |
| 2014 FY | 102.34 Million USD | 31.65% |
| 2014 Q4 | 24.69 Million USD | -23.53% |
| 2014 Q1 | 17.46 Million USD | 10.27% |
| 2014 Q2 | 27.9 Million USD | 59.76% |
| 2014 Q3 | 32.28 Million USD | 15.71% |
| 2013 Q3 | 18.49 Million USD | -9.52% |
| 2013 Q4 | 15.83 Million USD | -14.36% |
| 2013 Q1 | 22.96 Million USD | 5.3% |
| 2013 FY | 77.73 Million USD | 0.55% |
| 2013 Q2 | 20.44 Million USD | -10.99% |
| 2012 Q3 | 19.97 Million USD | 15.22% |
| 2012 Q2 | 17.33 Million USD | -4.75% |
| 2012 Q1 | 18.19 Million USD | 12.6% |
| 2012 FY | 77.31 Million USD | 11.73% |
| 2012 Q4 | 21.8 Million USD | 9.2% |
| 2011 FY | 69.19 Million USD | -3.28% |
| 2011 Q4 | 16.16 Million USD | 1.04% |
| 2011 Q1 | 19.67 Million USD | 13.18% |
| 2011 Q2 | 17.36 Million USD | -11.72% |
| 2011 Q3 | 15.99 Million USD | -7.9% |
| 2010 Q3 | 18.4 Million USD | -0.34% |
| 2010 Q1 | 17.29 Million USD | 25.3% |
| 2010 Q2 | 18.46 Million USD | 6.75% |
| 2010 FY | 71.53 Million USD | 29.05% |
| 2010 Q4 | 17.38 Million USD | -5.54% |
| 2009 Q4 | 13.8 Million USD | 1.4% |
| 2009 FY | 55.43 Million USD | -9.44% |
| 2009 Q3 | 13.61 Million USD | 4.57% |
| 2009 Q2 | 13.01 Million USD | -13.23% |
| 2009 Q1 | 15 Million USD | 49.22% |
| 2008 Q2 | 16.61 Million USD | -16.68% |
| 2008 Q1 | 19.93 Million USD | -14.48% |
| 2008 FY | 61.21 Million USD | -28.14% |
| 2008 Q4 | 10.05 Million USD | -31.21% |
| 2008 Q3 | 14.61 Million USD | -12.02% |
| 2007 Q4 | 23.31 Million USD | 15.47% |
| 2007 Q3 | 20.18 Million USD | -14.53% |
| 2007 Q2 | 23.62 Million USD | 30.78% |
| 2007 Q1 | 18.06 Million USD | -26.06% |
| 2007 FY | 85.18 Million USD | 29.76% |
| 2006 Q1 | 9.19 Million USD | -8.67% |
| 2006 Q2 | 14.33 Million USD | 55.93% |
| 2006 FY | 65.65 Million USD | 76.74% |
| 2006 Q3 | 17.68 Million USD | 23.36% |
| 2006 Q4 | 24.42 Million USD | 38.11% |
| 2005 Q3 | 9.11 Million USD | -8.53% |
| 2005 Q4 | 10.06 Million USD | 10.44% |
| 2005 FY | 37.14 Million USD | 17.28% |
| 2005 Q1 | 7.99 Million USD | 0.57% |
| 2005 Q2 | 9.96 Million USD | 24.65% |
| 2004 Q3 | 7.94 Million USD | -7.48% |
| 2004 Q4 | 7.95 Million USD | 0.06% |
| 2004 Q1 | 7.19 Million USD | 138.68% |
| 2004 FY | 31.67 Million USD | 70.37% |
| 2004 Q2 | 8.58 Million USD | 19.43% |
| 2003 FY | 18.59 Million USD | -7.45% |
| 2003 Q2 | - USD | 100.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q1 | -4.71 Million USD | 0.0% |
| 2003 Q4 | -18.59 Million USD | 0.0% |
| 2002 FY | 20.08 Million USD | -8.24% |
| 2001 FY | 21.89 Million USD | 86.81% |
| 2000 FY | 11.71 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -2555.379% |
| Alpha Teknova, Inc. | 45.85 Million USD | -377.867% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | -11.818% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -388.574% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | -37.647% |
| Cosmos Health Inc. | 26.18 Million USD | -737.045% |
| Journey Medical Corporation | 54.59 Million USD | -301.409% |
| Embecta Corp. | 528.4 Million USD | 58.527% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 19.401% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 62.857% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 32.855% |
| PainReform Ltd. | 9.58 Million USD | -2186.571% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1569.744% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1569.744% |
| SCYNEXIS, Inc. | 51.84 Million USD | -322.668% |
| Safety Shot Inc | 12.1 Million USD | -1709.666% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -7040.162% |
| Procaps Group, S.A. | 199.47 Million USD | -9.86% |
| Theratechnologies Inc. | 72.75 Million USD | -201.205% |
| Harrow Health, Inc. | 89.97 Million USD | -143.568% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -2219.977% |
| Biofrontera Inc. | 39.95 Million USD | -448.425% |
| DURECT Corporation | 43.71 Million USD | -401.304% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 58.575% |
| Cronos Group Inc. | 96.7 Million USD | -126.602% |
| OptiNose, Inc. | 85.1 Million USD | -157.509% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 5.591% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -459.714% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 2392.072% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 30.238% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -2152.068% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -409.159% |
| Radius Health, Inc. | 265.92 Million USD | 17.593% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -1483.199% |
| ProPhase Labs, Inc. | 37.85 Million USD | -478.952% |
| Phibro Animal Health Corporation | 260.29 Million USD | 15.81% |
| Procaps Group S.A. | 187.24 Million USD | -17.037% |
| Alvotech | 285.43 Million USD | 23.225% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -2130.483% |
| Viatris Inc. | 5.96 Billion USD | 96.327% |
| Rockwell Medical, Inc. | 15.37 Million USD | -1325.426% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -266.218% |
| SIGA Technologies, Inc. | 22.04 Million USD | -894.169% |
| Tilray Brands, Inc. | 251.35 Million USD | 12.815% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -346.888% |
| Shineco, Inc. | 17.94 Million USD | -1120.997% |
| PetIQ, Inc. | 192.72 Million USD | -13.709% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -5390.79% |
| Incannex Healthcare Limited | 30.05 Million USD | -629.195% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 86.273% |
| Alimera Sciences, Inc. | 62.64 Million USD | -249.843% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -28640.629% |
| Assertio Holdings, Inc. | 368.58 Million USD | 40.544% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -3623.428% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -1130.562% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -935.217% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -941.46% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | -32.843% |
| Hempacco Co., Inc. | 7.59 Million USD | -2784.835% |
| Talphera, Inc. | 11.99 Million USD | -1727.122% |
| Alvotech | 285.43 Million USD | 23.225% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | -55.738% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 36.461% |
| Currenc Group, Inc. | 24 Million USD | -813.025% |
| Kamada Ltd. | 45.42 Million USD | -382.422% |
| Indivior PLC | 911 Million USD | 75.945% |
| Evoke Pharma, Inc. | 12.4 Million USD | -1665.925% |
| Flora Growth Corp. | 10.57 Million USD | -1971.51% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -941.46% |
| Evolus, Inc. | 189.75 Million USD | -15.486% |
| HUTCHMED (China) Limited | 436.23 Million USD | 49.764% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -42.178% |
| Akanda Corp. | 3.48 Million USD | -6190.929% |